Carotid artery stenting: current and emerging options

Abstract: Carotid artery stenting technologies are rapidly evolving. Options for endovascular surgeons and interventionists who treat occlusive carotid disease continue to expand. We here present an update and overview of carotid stenting devices. Evidence supporting carotid stenting includes randomized controlled trials that compare endovascular stenting to open surgical endarterectomy. Carotid technologies addressed include the carotid stents themselves as well as adjunct neuroprotective devices. Aspects of stent technology include bare-metal versus covered stents, stent tapering, and free-cell area. Drug-eluting and cutting balloon indications are described. Embolization protection options and new direct carotid access strategies are reviewed. Adjunct technologies, such as intravascular ultrasound imaging and risk stratification algorithms, are discussed. Bare-metal and covered stents provide unique advantages and disadvantages. Stent tapering may allow for a more fitted contour to the caliber decrement between the common carotid and internal carotid arteries but also introduces new technical challenges. Studies regarding free-cell area are conflicting with respect to benefits and associated risk; clinical relevance of associated adverse effects associated with either type is unclear. Embolization protection strategies include distal filter protection and flow reversal. Though flow reversal was initially met with some skepticism, it has gained wider acceptance and may provide the advantage of not crossing the carotid lesion before protection is established. New direct carotid access techniques address difficult anatomy and incorporate sophisticated flow-reversal embolization protection techniques. Carotid stenting is a new and exciting field with rapidly advancing technologies. Embolization protection, low-risk deployment, and lesion assessment and stratification are active areas of research. Ample room remains for further innovations and developments.

Keywords: carotid devices, carotid stent, embolization protection, carotid stenosis, endovascular carotid

Introduction
Ramsay-Hunt reported in 1913 the clinicopathological findings of what he called “thrombotic hemiplegia,” where stroke patients were found to have a weakened carotid pulse, and postmortem pathology revealed carotid thrombus ipsilateral to gross ischemic changes in the brain.1 Cervical carotid artery stenosis was recognized by C Miller Fisher in the 1950s to be a major cause of stroke.2 Carotid endarterectomy has been implemented in the at-risk patient pool with significant success in reducing the risk of subsequent stroke compared to medical therapy alone.3–5 The innovative options offered by endovascular techniques have created a rapidly evolving field of medical devices whose judicious use allows for safe, often less invasive, alternatives to carotid
endarterectomy for carotid revascularization. Carotid stenting is now a widely accepted alternative to endarterectomy in specific situations. We here systematically describe the current state of carotid revascularization devices and the evidence to support them. Although endovascular treatment of occlusive carotid disease is indispensable during acute stroke intervention, we will focus predominantly on elective and semielective revascularization.

The carotid artery is unique because of its end organ. Whereas the primary concern during revascularization in peripheral vessels is restoration of flow and hemodynamic balance, even minor distal embolization in the carotid artery can be associated with devastating neurological injury. Conversely, although distal embolization remains a concern when instrumenting and manipulating intracranial vasculature, these vessels lack significant muscularity and have a lower resistance bed. The unique goal of carotid device technology is to achieve adequate endoluminal recanalization against a centripetal muscular force, while minimizing distal embolic events.

Conceptually, we categorize carotid technologies into three groups: stent, balloon angioplasty, and embolization prevention devices. Other miscellaneous technologies are also presented.

Stents

Background

A stent is a scaffolding device that is often tubular and is used to hold tissue in a specific stretched or taut position. Modern intravascular stents are available in balloon-expandable and self-expanding varieties. In the setting of carotid bifurcation disease where prominent chronic compressive forces and a substantial drop in caliber between the common and internal carotid arteries (ICAs) as well as their mobile nature, self-expanding stents (eg, Wallstent; Boston Scientific, Natick, MA, USA) have become standard of care. Though early carotid interventionists reserved balloon-expandable stents for especially tortuous, ostial, and very calcified lesions, advances in stent technology have reduced the role of this type of stent even in those lesions. The two most common alloys for carotid stents are cobalt-chromium and nickel-titanium (known as nitinol). Self-expanding stents are usually manufactured in a ready-to-use compressed form within a catheter-based sheath that functions as a delivery system. After insertion into the target artery, expansion is achieved by “unsheathing” the stent, at which time the mechanically predetermined centrifugal spring-like force is no longer neutralized by the sheath structure and the stent expands.

Carotid stenting trials

The initial impetus to develop endovascular alternatives to endarterectomy was to provide a noninferior treatment modality for patients who were suboptimal surgical candidates. Medical morbidities that increase surgical risk include severe cardiac, pulmonary, and renal disease. Poor anatomical factors include a very high carotid bifurcation, in which case carotid access/exposure poses an inevitable risk of mandibular dislocation. Historically, adjunct procedures to improve access to the carotid artery have included mandibulonasal wiring, mandibular subluxation, and mandibular condyle resection. Other anatomic considerations include previous extensive neck dissection and/or irradiation. Patients with previous injury to nervous structures with partial laryngeal palsy are at high risk for developing debilitating and life-altering pharyngolaryngeal dysfunction with surgery contralateral to the compromised side. Prohibitive spinal immobility and other anatomic hindrances to intubation are also considerations.

Early endovascular alternatives to carotid endarterectomy were predominantly balloon-based. A randomized study comparing carotid endarterectomy and angioplasty was terminated after enrolling only ten endarterectomy and seven angioplasty patients due to a high rate of mortality in the latter group. The Carotid and Vertebral Artery Transluminal Angioplasty Study investigators found no significant difference in rates of stroke or death between carotid balloon angioplasty with or without stenting and endarterectomy in symptomatic carotid stenosis cases. However, the study was underpowered to make a claim of equal efficacy.

Trials conducted in North America (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy [SAPPHIRE]) and Europe (Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis [EVA-3S] and Stent-Protected Angioplasty versus Carotid Endarterectomy [SPACE]) attempted to demonstrate noninferiority for stenting compared to endarterectomy. The SAPPHIRE trial enrolled high-risk (eg, significant cardiac disease, recurrent stenosis, and age >80 years) symptomatic and asymptomatic patients. The composite end point (death, stroke, or myocardial infarction [MI] within 30 days of intervention or death or ipsilateral stroke within 1 year) occurred less frequently
in the stenting with embolic protection group compared with the endarterectomy group in a noninferiority analysis (12.2% versus 20.1%, \( P=0.004 \)). The EVA-3S trial, on the other hand, was terminated prematurely because of safety and futility concerns. A significant increase in 30-day risk of stroke or death was found in the stenting group compared to the endarterectomy group (9.6% versus 3.9%, \( P=0.01 \)).\(^{20}\) Follow-up results demonstrated a higher cumulative probability of periprocedural stroke or death and nonprocedural ipsilateral stroke after up to 4 years in the stenting group (11.1% in the stenting group versus 6.2% in the endarterectomy group, \( P=0.03 \)).\(^{21}\) In the SPACE trial, no significant difference was found in the 30-day and 2-year risk of stroke or death between stenting and endarterectomy.\(^{24}\) Nevertheless, the study failed to prove noninferiority, likely due to insufficient power. Additionally, the rate of recurrent stenosis was higher in the stenting group. Though neither European trial proved noninferiority of stenting, data suggested that the greatest risk was concentrated in the periprocedural period and that the risk of mid-term to long-term recurrent stroke was low. Both were criticized for lacking standardization of stent type and neurointerventionist experience.

More recently, the International Carotid Stenting Study (ICSS) investigators randomized 1,713 patients with >50% symptomatic carotid stenosis in 50 mostly European centers.\(^{25}\) Within the 120-day follow-up period, the incidence of stroke, death, or periprocedural MI was significantly higher in the stenting group. Endarterectomy was significantly more likely to be associated with cranial neuropathies and wound complications. In a subsequent subset analysis, significantly more ischemic brain lesions were found on magnetic resonance (MR) diffusion-weighted imaging after stenting compared to endarterectomy.\(^{26}\)

The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is the largest randomized controlled trial comparing stenting with embolic protection “whenever feasible” and endarterectomy in both symptomatic and asymptomatic carotid stenosis.\(^{7}\) Patients from 117 centers in North America were enrolled in the trial. Up to 4 years of follow-up data were collected. No statistical difference was noted in the primary end point of a composite of 30-day stroke, MI, or death. Isolation of the end points revealed a higher risk of periprocedural stroke or death in the stenting group (4.4% versus 2.3%, \( P=0.005 \)), whereas MI was more common in the endarterectomy group (1.1% versus 2.3%, \( P=0.03 \)). The change in measured outcomes in this trial compared to previous trials has been attributed to improving technology and advanced interventionist skills. More comprehensive screening protocols have also been invoked; for example, the overall rate of MI was much higher in CREST than in ICSS (1.7% versus 0.5%), likely due to cardiac biomarkers being screened in all patients in CREST and only in patients complaining of cardiac symptoms in ICSS.

The CREST-2 trial currently under way utilizes a four-armed parallel study design to compare composite 30-day stroke and death outcome differences between medical therapy alone versus endarterectomy and stenting, respectively, in conjunction with best medical therapy, in an asymptomatic patient pool.\(^{27}\) Once the two parallel studies are completed, the difference in gain, if any, from adding one of the two revascularization procedures to medical therapy will be compared.

**Evolution of stent technology**

The Wallstent (Boston Scientific), initially approved for biliary use in Europe, has subsequently been approved for use in various internal organs and the iliac artery.\(^{10,28,29}\) Use in the carotid artery has been off-label. Given its limited expansion force, the diameter of the Wallstent must usually be oversized by 2–3 mm relative to the lumen of the ICA. Additionally, it is difficult to predict where and to what degree the stent will be foreshortened, challenging the interventionist’s capacity to ensure that the lesion is entirely crossed by the stent. Further, its sharp wire ends create the potential for intimal injury. In cases of vessel tortuosity, this problem is compounded by unevenly distributed circumferential pressure, predisposing to kinking at bends and flaring at the ends. The Wallstent is an alloy of cobalt, chromium, nickel, molybdenum, iron, manganese, and stainless steel woven into a cylindrical superstructure. Tantalum has been added to its composition to enhance radiopacity. The Symphony (Boston Scientific) is a welded nitinol stent that is more rigid than the Wallstent and has a tendency to kink in tortuous vessels. It is thus primarily used for common carotid and brachiocephalic arteries with fairly straight trajectories. It has been reported to foreshorten less than 8%.\(^{30}\) The SMART Stent (Cordis Corporation, Bridgewater, NJ, USA) is laser cut from a single nitinol tube and has a deployment mechanism and wall coverage that are similar to the Wallstent. The Acculink (Abbott Vascular, Abbott Park, IL, USA) was specifically designed for use in the extracranial carotid artery. Numerous other unique sophisticated stent designs are available at present, some of which are listed in Table 1.
Table 1 Characteristics of commonly used carotid stents

<table>
<thead>
<tr>
<th>Stent</th>
<th>Manufacturer</th>
<th>Cell type</th>
<th>Free cell area (mm²)</th>
<th>Nontaper option</th>
<th>Taper option</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wallstent</td>
<td>Boston Scientific (Natick, MA, USA)</td>
<td>Closed</td>
<td>1.08</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Xact</td>
<td>Abbott Vascular (Abbott Park, IL, USA)</td>
<td>Closed</td>
<td>2.74</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>NexSert</td>
<td>Boston Scientific</td>
<td>Closed</td>
<td>4.70</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Precise</td>
<td>Cordis (Bridgewater, NJ, USA)</td>
<td>Open</td>
<td>5.89</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Exponent</td>
<td>Medtronic (Minneapolis, MN, USA)</td>
<td>Open</td>
<td>6.51</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Protégé</td>
<td>Covidien (Irvine, CA, USA)</td>
<td>Open</td>
<td>10.71</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Acculink</td>
<td>Abbott Vascular</td>
<td>Open</td>
<td>11.48</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Zilver S18® RX</td>
<td>Cook Medical (Bloomington, IN, USA)</td>
<td>Open</td>
<td>12.76</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Cristallo Ideale</td>
<td>Medtronic</td>
<td>Hybrid: closed-cell center; open-cell ends</td>
<td></td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Sinus-Carotid-Rx</td>
<td>Optimed (Ettlingen, Germany)</td>
<td>Hybrid: open-cell center; closed-cell ends</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: N, no; Y, yes.

Open-cell versus closed-cell design

The open-cell versus closed-cell distinction identifies the free-cell area or the amount of space between the latticework of a stent. In closed-cell stents, each free space (cell) between the tines of a stent is completely separated from all other spaces by tines, whereas in open-cell designs the cell is connected to other cells through incomplete tines. An open-cell stent allows for larger uncovered gaps and is more malleable, making it better suited for tortuous areas. The reduced need for manipulation associated with this stent design is likely to reduce embolic potential, as well as kinking. Conversely, the greater free-cell area allows for more exposed plaque, possibly increasing embolic potential. Some studies suggest that closed-cell stents afford more protective lesion coverage and a possible decrease in transient ischemic attacks. Yet, another study found no statistically significant differences in neurologic complications, stroke, and mortality risk between carotid stent cell designs. It should be noted that dichotomizing free-cell area into “open” and “closed” cell designs is slightly misleading. Not only is there variability in quantitative free-cell area among so-called “open-cell” stents, but also the final free-cell area will inevitably be significantly affected by the size of stent chosen for a particular carotid artery caliber and lesion – ie, whether the interventionist chooses to “oversize” or “undersize.” Additionally, newer hybrid stent designs have attempted to combine the benefits of open- and closed-cell designs by introducing a variable free-cell area in different regions of the stent (Table 1).

Bare-metal versus covered stents

Some studies suggest that covered-cell stents afford more protective lesion coverage and a possible decrease in transient ischemic attacks. However, the implications for clinical correlates and restenosis rate are unclear.

A prospective randomized trial found no significant difference in diffusion restricting lesions on MR imaging when comparing closed- and open-cell designs. A retrospective comparison found that the open-cell design was associated with significantly fewer diffusion-weighted detectable embolic events on MR imaging when carotid atherosclerosis was treated without distal protection devices. However, the difference in rate of clinical events did not reach statistical significance. It should be noted that these retrospective studies do not address the possibility that the embolic imaging findings may be related to the necessary process of crossing the lesions with the protection device itself before distal protection is established.

Some studies have been mixed in demonstrating a clinical difference between bare-metal and covered stents. Materials used to cover stents include porous expanded polytetrafluoroethylene polymer and semipermeable porous silicone-polyurethane. An extensive review of covered stents from a materials engineering perspective has been published. One disadvantage of covered stents is their propensity for blocking branch vessels. Because carotid artery disease usually involves the carotid bifurcation and the cervical carotid artery, this is unlikely to be a major concern except in the setting where the stent is anticipated to cross the external carotid
artery (ECA). Although occlusion of the extracranial carotid circulation may be of limited consequence in the setting of robust ICA flow, patients with long-standing cerebrovascularopathy and chronic ICA low-flow states are often dependent on extensive networks of angiographically visible and hidden extracranial-to-intracranial anastomoses.46

A covered stent with an opening on the side has been devised but has not gained wide acceptance because of the difficulty in deploying it with the opening in the exact orientation of the ECA. A recent stent design places slits on a covered stent in the direction of the long axis of the stent. This design is intended to allow blood flow into the ECA while covering the plaque and preventing embolization of atherosclerotic debris.7 This device is awaiting clinical testing.

Stent tapering

The caliber of the common carotid artery (CCA) is usually significantly and predictably larger than that of the ICA. Endovascular attempts to address this issue have included the use of tapered stent designs. In a nontapered stent, the distal and proximal diameters of the stent are engineered to be the same. Manufacturers have argued that self-expanding stents are naturally “self-tapering” and will contour to the inner lumen of the carotid artery. Tapered stents provide a decrement in diameter in the proximal and distal edges. Two subcategories are available. One type, represented by the Acculink and Xact stents (Abbott Vascular, Abbott Park, IL, USA), incorporates a gradual diminution of diameter, referred to as a conical taper. A “shouldered” variety, exemplified by the Protégé stent (Covidien, Irvine, CA, USA), has a punctuated decrease in stent caliber. The transitional point is referred to as the shoulder and should be positioned at the level of the ECA takeoff. Data regarding possible benefits of tapered stents is still inconclusive.49

Unfavorable anatomy and direct carotid access

Direct carotid artery puncture provides enhanced access in tortuous vessels.50,51 Initially reported in intracranial angioplasty and stenting cases,52 it has now been extended for use in carotid bifurcation lesions. Although age >70 or 80 years is often presented as an intrinsic independent risk factor for embolic events with endovascular stenting, close reevaluation has found that unfavorable arch anatomy is most important in predisposing for adverse embolic events, rather than age alone.53–55 Vessel tortuosity and atherosclerotic aortic arch disease were found to be the predominant factors contributing to the increased rate of stroke associated with carotid stenting in patients >70 years compared with carotid stenting in younger patients and endarterectomy among all ages; this suggests that the increased risk of embolic events is likely related to difficult access.54,55 When patients with an acute angle between the aortic arch and the stented CCA were compared to patients with more favorable arch anatomy in a high-volume single-center retrospective study, a significant difference (P=0.0073) in adverse embolic events was observed.56 When controlling for arch anatomy, no statistically significant difference between patients aged ≥80 years and <80 years could be found.

Balloon angioplasty for in-stent restenosis

Cutting balloon

In-stent restenosis has been reported in 8% of carotid stenting cases.56 The CREST investigators reported a 6% restenosis rate in both stenting and surgical endarterectomy cases.7 Consensus and rigorous evidence are lacking for the management of in-stent restenosis. Successful use of a cutting balloon, previously well known to interventional cardiologists for partial atherectomy in cases of primary or delayed lesion recurrence after coronary stenting, has been reported in small carotid stenting case series.57–59 The same technology has been successfully reported for severely calcified primary carotid lesions as an adjunct to stenting to minimize hemodynamic instability from carotid bulb compression.60

Drug-eluting balloon

Drug-eluting balloon technology has a long track-record in the coronary arteries and has recently been applied to the carotid artery. The dominant opinion is that these devices should not be used for direct mechanical dilatation but should rather be used as a drug delivery system once predilation has been successfully achieved.61,62

Emboli prevention

Statistically significant microembolic events have been recorded using transcranial Doppler ultrasonography during carotid stenting.63 Noninferiority of stenting with distal protection compared to historical results with endarterectomy has been demonstrated64 and was confirmed in the prospective randomized controlled SAPHIRE trial.22 Periprocedural neuroprotection is thought to provide clinical benefit by preventing distal migration of macroscopic and microscopic emboli that may cause clinically significant ischemic events.
Three categories of embolic prevention systems are currently available. Distal nonocclusive systems ideally prevent distal embolization while preserving distal flow. Distal occlusive systems prevent flow of both blood and embolic material distally. Proximal devices occlude CCA and ECA flow, thereby producing flow reversal from the ICA, removing embolic material from the carotid bifurcation region into the CCA, and, eventually, returning blood via a filter into the venous system (GORE Flow Reversal System; WL Gore and Associates, Flagstaff, AZ, USA) or direct aspiration (Mo.Ma; Medtronic, Minneapolis, MN, USA).

**Distal protection**

Stenting with distal filtration technologies (distal nonocclusive systems) demonstrated noninferiority to endarterectomy, and outcomes following multicenter cohort studies as well as the SAPPHIRE trial were promising. The Angioguard (Cordis, Bridgewater, NJ, USA) used in SAPPHIRE is a low profile guidewire-based filtering device that allows for easy simultaneous delivery of stents and balloons. The wire is then pulled out at the end of the case, along with the filter basket. The NeuroShield Cerebral Protection System (MedNova, Galway, UK; subsequently acquired by Abbott Vascular and marketed as the Emboshield) is a temporary implantable design composed of a porous nonocclusive polyurethane membrane deployed over a preformed nitinol expansion wire construct. A retrieval system is included with a flexible distal portion to the outer catheter that expands as the inner catheter is passed. Commonly used distal protection devices are listed in Table 2.

**Table 2 Distal embolization protection devices**

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Pore size (µm)</th>
<th>Vessel size (mm)</th>
<th>Fixed wire</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gore</td>
<td>Gore (Newark, DE, USA)</td>
<td>100</td>
<td>2.5–5.5</td>
<td>Y</td>
</tr>
<tr>
<td>Embolic Filter</td>
<td>Emboshield (Abbott, Chicago, IL, USA)</td>
<td>120</td>
<td>2.5–7</td>
<td>N</td>
</tr>
<tr>
<td>Spider</td>
<td>Covidien (Irvine, CA, USA)</td>
<td>50–300</td>
<td>3.0–7.0</td>
<td>N</td>
</tr>
<tr>
<td>Accunet</td>
<td>Abbott</td>
<td>125</td>
<td>3.2–5</td>
<td></td>
</tr>
<tr>
<td>FilterWire EZ</td>
<td>Boston Scientific (Natick, MA, USA)</td>
<td>110</td>
<td>3.5–5.5</td>
<td>Y</td>
</tr>
<tr>
<td>FiberNet</td>
<td>Medtronic (Minneapolis, MN, USA)</td>
<td>&gt;40</td>
<td>3.5–7</td>
<td>Y</td>
</tr>
<tr>
<td>Angioguard</td>
<td>Cordis (Bridgewater, NJ, USA)</td>
<td>100</td>
<td>4.5–7.5</td>
<td>Y</td>
</tr>
</tbody>
</table>

Abbreviations: N, no; Y, yes.

That distal protection devices perform their intended function of catching emboli is clear, yet the incidence of peri-procedural ischemic events has not been found to be affected by the load of embolic material found in distal filters. Despite initially promising multicentre results, retrospective studies in which distal protection devices were used have not shown significantly improved outcomes, though a trend toward decreased risk of embolic ischemic events may be present. However, it should be noted that in the United States, carotid stenting is not reimbursed by Medicare unless it is performed with distal embolic protection.

Several disadvantages of distal protection devices have been described. These devices must be advanced across the stenotic lesion before embolic protection can be established; and during this process, distal embolization may occur. Their size is typically in the range of 3-French, and therefore they are generally stiffer and bulkier than proximal occlusion devices, increasing navigation difficulty and the likelihood of aggressive vessel/intimal manipulation across tortuous vessels or critically stenotic carotid arteries. They are also frequently associated with focal vasospasm and, infrequently, vessel injury. Further, retrieval and removal of a deployed protection device may provide yet another opportunity for peri-procedural distal embolization.

Concentric versus eccentric filter

Concentric and eccentric distal protection devices differ based on the position of the wire that tethers the filter: centered versus to the side. Although one study identified no difference between filter type, another study reported a statistically significant decrease in embolic events with eccentric filters when analyzing all clinical findings, including...
transient ischemic attacks. However, this difference was not significant when transient clinical findings were excluded and only stroke and death were analyzed. Eccentric filters may engage the vessel wall more stably, allowing for better embolization protection.

**Distal occlusion**
Distal occlusion, as opposed to distal filtration, involves isolation of the distal cerebrovascular distribution from the atherosclerotic carotid segment being manipulated. This can be most simply done with temporary balloon occlusion, which was the first distal embolization protection mechanism reported. A more sophisticated approach is required to ensure that the embolic material is cleared before the balloon is removed. This is accomplished by applying suction to the sheath proximally or attempting to flush the embolic material proximally in hope of driving the debris into the external carotid system. The GuardWire Protection system (PercuSurge, Sunnyvale, CA, USA), for example, is designed for distal occlusion that is supplemented with an aspiration catheter called the Export (Medtronic). Despite the difficulties associated with debris removal with distal occlusion devices rather than distal protection devices, there is likely a decreased risk of device-induced vasospasm with balloon devices compared to filter devices. A significantly greater likelihood of the need for unprotected predilation was found with distal filter devices compared to distal balloon occlusion devices. Some authors recommend the use of filter devices in preference to balloon occlusion because of a somewhat lower risk of distal embolization, unless the vessels are tortuous and critically narrowed. Though concern has been expressed regarding increased radiation exposure with the added use of distal embolic protection devices, this has not been borne out by quantitative dosimetric studies.

**Flow reversal**
Proximal occlusion aims to isolate the diseased area undergoing intervention from the distal area but rather to create flow reversal from contralateral carotid and vertebrobasilar collaterals intracranially, thereby flushing emboli proximally into the CCA. Although endarterectomy has the advantage of allowing the placement of a shunt to direct flow proximal to the CCA clamp to distal to the ICA clamp, yet another maneuver utilized in endarterectomy is replicated by flow reversal technology. Unclamping is performed in a specific order – first the ICA, then the ECA, and finally the CCA – to allow for temporary flow reversal and flushing of potentially embolic material into the extracranial carotid circulation. An advantage of proximal occlusion devices over distal protection devices is that the lesion is not crossed in an unprotected state.

The initial introduction of flow reversal technology for proximal embolic protection was met with skepticism given the significantly lower resistance bed that comprises the intracranial carotid system compared to the extracranial carotid system; even small extracranial collateral communications from the external carotid or vertebrobasilar system may compromise the ability to achieve meaningful flow reversal. Early authors argued that to achieve flow reversal, one must first induce flow stasis by placing the occlusive balloon distal to the ECA takeoff; and if this is done, clearance of embolic materials becomes problematic.

A creative solution to this dilemma was the development of a proximal protection device in which a triple-lumen catheter with a double-balloon was utilized to occlude the CCA and ECA; the reversed flow was then directed through the catheter to a filtered external femoral venous system. The popularity of proximal protection increased with the introduction of sophisticated technologies, such as the GORE Flow Reversal and Mo.Ma systems (Table 3). Although the GORE system induces true flow reversal, as described above, Mo.Ma is simply a focal flow arrest without any venous return. Trials and meta-analyses confirm a 30-day stroke risk of <2% associated with carotid stenting using flow reversal with both systems. It should be noted that there is a reported intolerance to flow arrest or flow reversal in a small subset of patients (<2%) with isolated intracranial circulation.

An innovative approach aimed at obviating the need for accessing an unfavorable aortic arch is being evaluated in the Reverse Flow Used During Carotid Artery Stenting Procedure safety and efficacy study. The MICHI

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>External carotid artery occlusion</th>
<th>Flow reversal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gore Flow Reversal System</td>
<td>WL Gore and Associates (Flagstaff, Arizona, USA)</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Mo.Ma</td>
<td>Medtronic (Minneapolis, MN, USA)</td>
<td>Y</td>
<td>N (focal flow arrest without venous return)</td>
</tr>
<tr>
<td>MICHI Neuroprotection System</td>
<td>Silk Road Medical (Sunnyvale, CA, USA)</td>
<td>N</td>
<td>Y</td>
</tr>
</tbody>
</table>

**Abbreviations:** N, no; Y, yes.
Neuroprotection System (Silk Road Medical Inc., Sunnyvale, CA, USA) has demonstrated initial safety and noninferiority to historical endarterectomy data using direct carotid puncture access to establish flow reversal and diversion into the femoral venous system with the intent to maximize the interventionist’s control of flow parameters. A case in which this transcervical access neuroprotection system was used for carotid stenting is illustrated in Figure 1.

Comparison of embolization prevention devices

Variable results with embolic protection devices have been reported. Recent MR diffusion imaging and ultrasound transcranial Doppler data have shown embolic events to be less common with flow reversal than distal filter protection. The opposite conclusion was reached by another group studying postprocedure follow-up MR imaging diffusion restriction. The results of a study comparing carotid stenting with flow reversal, carotid stenting with distal filter protection, and endarterectomy suggest that the increased risk of perioperative stroke in carotid stenting compared to endarterectomy may be applicable to stenting with distal filter devices but not with flow reversal. However, no significant differences among these techniques were found when long-term outcomes, such as death and neurological disability, were assessed. Another study found no difference between distal and proximal protection outcomes but noted that distal filters were used in more symptomatic and complex lesions as determined by plaque ulceration, calcification, and length. The variable results may be due to the novelty of the various embolic-protection devices and their fairly recent introduction into broad use. Flow-reversal is associated with approximately five more steps than distal protection, perhaps making the use of flow-reversal devices more learning-curve and operator-experience dependent.

Modeling and risk stratification

As stated above in reference to the Wallstent, one problem that is commonly encountered during carotid stenting is the inability to predict the exact final position of the stent. The use of finite-element analysis to study the effect of carotid stenting on each individual vessel wall is currently a costly and lengthy process that requires several days and significant technological resource expenditure. With improvements in modeling efficiency and computational technology, such analyses may in the future be a helpful addition to clinical practice.

Figure 1 Case illustration of the Reverse Flow Used During Carotid Artery Stenting Procedure (ROADSTER).
Notes: A 73-year-old man with multiple medical comorbidities, including coronary artery disease status post recent coronary artery bypass grafting, hypertension, and diabetes mellitus, was found to have asymptomatic severe right carotid stenosis on a cervical computed tomographic (CT) angiogram (A). The patient was a poor candidate for carotid endarterectomy owing to body habitus and high lesion (up to C2 vertebral body) and a poor candidate for transfemoral carotid artery stenting due to arch anatomy and a tortuous proximal right common carotid artery (CCA) (B, arrows in CT angiogram three-dimensional reconstruction). He was enrolled in the ROADSTER study and treated via direct carotid artery access. A small incision was made above the right clavicle, and the right CCA was identified and isolated (C, intraoperative photograph). Note the importance of tack-up sutures (arrows) in the carotid sheath that elevated the CCA to the body surface for direct access. After insertion of an arterial access sheath and the MiCHi neuroprotection system (Silk Road Medical, Sunnyvale, California, USA) (D, arrowhead), an angiogram from the right CCA demonstrated 85% carotid stenosis (arrow). After successfully placing an Xact tapered stent (8×6×40 mm; Abbott Laboratories, Abbott Park, Illinois, USA) and performing balloon angioplasty, an angiogram from the right CCA (E) showed significantly improved vessel caliber and good stent apposition.
Carotid tortuosity can be categorized and quantified for risk-stratification on the basis of an intraprocedural angiogram or a preprocedural computed tomographic or MR luminogram. A group of clinicians in Poland have championed a “tailored” carotid artery stenting algorithm for the elderly; they posit that an intimate knowledge of the specific benefits and characteristics of each device and tailoring the specific combination of devices to the particular vessel anatomy, pathological process, and radiographic qualities of the patient may be especially important in older patients in whom the risks of carotid stenting are especially prominent.

Though at this time insufficiently generalizable or reproducible, a systematic, reportable algorithm may ensue with sufficient experience and effort.

Intravascular ultrasound
Ultrasound-based technologies and techniques can be used to identify and crudely quantify the echolucency of carotid plaque, which may be a marker for embolic potential. When choosing devices, relative embolic risk of the devices under consideration and characteristics of the patient’s plaque can be taken into account. Intravascular ultrasound (IVUS) is

Figure 2 Case illustration of the utility of intravascular ultrasound (IVUS).
Notes: A 60-year-old man presented with transient dysphasia and was found to have left carotid artery stenosis on angiography (A). After successfully placing an 8 mm×40 mm carotid Wallstent (Boston Scientific, Natick, MA, USA), IVUS examination demonstrated intraluminal thrombus (B, arrow), which did not resolve after aspiration. A second Wallstent (8 mm×30 mm) was placed to cover the thrombus (C), and poststenting angiogram from the left CCA showed good carotid revascularization (D).
Abbreviation: CCA, common carotid artery.
Acknowledgments
The authors thank Paul H Dressel, BFA for assistance with preparation of the illustrations and Debra J Zimmer for editorial assistance.

Author contribution
All authors are responsible for concepts and design, and all authors contributed intellectually. All authors acquired, analyzed, and interpreted the data. The manuscript was prepared by Morr. All authors reviewed and made critical revision of the manuscript.

Disclosure
Siddiqui’s research grants (not related to present study) include National Institutes of Health (coinvestigator: NINDS 1R01NS064592-01A1 and NIB1B5RO1 EB002873-07), University at Buffalo (Research Development Award). Financial interests include Hotspur, Intratech Medical, StimSox, Valor Medical, Blockade Medical, Lazarus Effect; associations as consultant include Codman and Shurtleff, Inc., Concentric Medical, Coviend Vascular Therapies, GuidePoint Global Consulting, Penumbra, Stryker Neurovascular, Pulsar Vascular; speakers’ bureaus include Codman and Shurtleff, Genentech; national steering committees member for Penumbra 3D Separator Trial, Coviend SWIFT PRIME Trial; advisory board involvement with Codman and Shurtleff, Coviend Vascular Therapies; honoraria incurred from Abbott Vascular and Codman and Shurtleff, Inc. for training other neurointerventionists in carotid stenting and for training physicians in endovascular stenting for aneurysms. Lin and Morr report no conflicts of interest in this work.

References
4. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70%–99%) or with mild (0%–29%) carotid stenosis. European Carotid Surgery Trialists’ Collaborative Group. Lancet. 1991;337(8752):1235–1243.


